Welcome to Pangaea insights
Our collective intelligence provides an unrivalled breadth and depth of knowledge.
Pangaea’s ongoing relationships with key industry stakeholders facilitate continuous updates and dissemination of relevant market intelligence. Check back often for new posts!
Pangaea Express: PSPs Regulations in the updated IMC Code
December 12, 2019
While the changes to the PSP funding may not be a surprise to some given the growing lens of transparency within the industry, this revision could have significant implications.
Sunsetting the brand: Is this the best strategy when a product will lose exclusivity?
November 28, 2019
Loss of exclusivity requires alot of effort with minimal financial reward for maintaining the life of a brand.
Pangaea Express: PMPRB Guidelines
November 22, 2019
The Draft PMPRB Guidelines were released yesterday to explain how the amended Patented Medicines Regulations, that go into effect July 1, 2020 will be implemented.
A generic biologic in Canada?
November 12, 2019
Forteo (teriparatide, Lilly) is a biologic manufactured using recombinant DNA technology.
Insights on External Deployment by the Pharmaceutical Industry
August 13, 2019
The ever-changing Canadian health care environment has forced the
pharmaceutical industry to rethink external deployment.
Pangaea Express: Announcement of Upcoming Patented Medicines Regulations Publication
August 9, 2019
Health Canada Officials provided an update today regarding the final Patented Medicines Regulations.
Pangaea Express: Mandatory Reporting by Hospitals of Serious ADRs and MDIs
July 9, 2019
The Regulations regarding mandatory reporting of serious adverse drug reactions (ADRs) and medical device incidents (MDIs) by hospitals, proposed last summer, have now been adopted and will come into effect by December 16, 2019.
Pangaea Express: Advisory Council of National Pharmacare Final Recommendations
June 13, 2019
Universal, single-payer, public pharmacare in Canada.
Pangaea Express: BC Bold on Biosimilars
May 28, 2019
It has been some time coming but the speculation is over now. BC is the first province to switch patients from certain innovator biologics to their biosimilars.
Pangaea Express: No more CADTH for Biosimilars
May 24, 2019
Biosimilars no longer need to be reviewed by CADTH.